ATE447970T1 - Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors - Google Patents

Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors

Info

Publication number
ATE447970T1
ATE447970T1 AT02712288T AT02712288T ATE447970T1 AT E447970 T1 ATE447970 T1 AT E447970T1 AT 02712288 T AT02712288 T AT 02712288T AT 02712288 T AT02712288 T AT 02712288T AT E447970 T1 ATE447970 T1 AT E447970T1
Authority
AT
Austria
Prior art keywords
agents
treatment
lpa receptor
receptor
lpa
Prior art date
Application number
AT02712288T
Other languages
English (en)
Inventor
Shinji Nakade
Daikichi Fukushima
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Application granted granted Critical
Publication of ATE447970T1 publication Critical patent/ATE447970T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT02712288T 2001-02-08 2002-02-07 Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors ATE447970T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001031827 2001-02-08
PCT/JP2002/001025 WO2002062389A1 (en) 2001-02-08 2002-02-07 Remedies for urinary diseases comprising lpa receptor controlling agents

Publications (1)

Publication Number Publication Date
ATE447970T1 true ATE447970T1 (de) 2009-11-15

Family

ID=18895852

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02712288T ATE447970T1 (de) 2001-02-08 2002-02-07 Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors

Country Status (6)

Country Link
US (1) US7288558B2 (de)
EP (1) EP1364659B1 (de)
JP (1) JP4396808B2 (de)
AT (1) ATE447970T1 (de)
DE (1) DE60234318D1 (de)
WO (1) WO2002062389A1 (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2312588T3 (es) * 2001-07-17 2009-03-01 Ono Pharmaceutical Co., Ltd. Regulacion de la secrecion del jugo pancreatico que comprende un agente de regulacion del receptor del lpa.
EP1550461A1 (de) * 2002-06-26 2005-07-06 Ono Pharmaceutical Co., Ltd. Mittel zur behandlung chronischer erkrankungen
CA2498944C (en) 2002-09-19 2011-05-17 Yasushi Kohno Amino alcohol derivatives, salts thereof and immunosuppressive agents
WO2004031118A1 (ja) * 2002-10-03 2004-04-15 Ono Pharmaceutical Co., Ltd. Ｌｐａ受容体拮抗剤
JP4523265B2 (ja) * 2002-11-13 2010-08-11 旭化成ファーマ株式会社 排尿障害治療用口腔内崩壊製剤
EP1602660B1 (de) 2003-02-18 2011-04-06 Kyorin Pharmaceutical Co., Ltd. Aminophosphonsäurederivate, deren additionssalze und s1p-rezeptormodulatoren
US20060160887A1 (en) * 2003-07-16 2006-07-20 Kyowa Hakko Kogyo Co., Ltd. Medicinal composition
WO2005012269A1 (ja) * 2003-08-05 2005-02-10 Ajinomoto Co., Inc. 新規アゾール化合物
US8197846B2 (en) * 2003-11-10 2012-06-12 Astellas Pharma Inc. Sustained release pharmaceutical composition
US8128958B2 (en) * 2003-11-10 2012-03-06 Astellas Pharma Inc. Sustained release pharmaceutical composition
WO2005058790A1 (ja) * 2003-12-19 2005-06-30 Ono Pharmaceutical Co., Ltd. リゾホスファチジン酸受容体拮抗作用を有する化合物およびその用途
BRPI0513110A (pt) * 2004-07-16 2008-04-29 Kyorin Seiyaku Kk medicamento compreendendo composto sulfeto diaril ou composto éter diaril tendo uma estrutura 2-amina-1, 3-propanediol tendo uma atividade de redução de linfócitos perifericamente circulante, em combinação com um agente imunosupressivo e/ou um agente antiinflamatório e método de expressão de prevenção do efeito secundário
RU2376285C2 (ru) 2004-10-12 2009-12-20 Киорин Фармасьютикал Ко., Лтд. Процесс получения гидрохлорида 2-амино-2-[2-[4-(3-бензилоксифенилтио)-2-хлорфенилэтил]-1,3-пропандиола] и его гидратов, а также промежуточные продукты их получения
BRPI0617077A2 (pt) * 2005-10-07 2015-01-06 Kyorin Seiyaku Kk Agente terapêutico para tratamento de doenças do fígado contendo 2-amina-1, 3-propanediol derivativo como ingrediente ativo, e método para tratamento de doenças do fígado
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
US8232319B2 (en) * 2006-08-08 2012-07-31 Kyorin Pharmaceutical Co., Ltd. Amino phosphate derivative and S1P receptor modulator having same as an active ingredient
SG174029A1 (en) * 2006-08-08 2011-09-29 Kyorin Seiyaku Kk Aminoalcohol derivative and immunosuppressant containing the same as active ingredient
US8466683B2 (en) * 2006-12-14 2013-06-18 Schlumberger Technology Corporation Determining properties of earth formations using the electromagnetic coupling tensor
US8871275B2 (en) 2007-08-08 2014-10-28 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
EP2042179A1 (de) * 2007-09-26 2009-04-01 sanofi-aventis Neue therapeutische Verwendung adrenerger alpha-1-Rezeptorantagonisten
WO2009099174A1 (ja) * 2008-02-07 2009-08-13 Kyorin Pharmaceutical Co., Ltd. アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤
EP2324852B1 (de) 2008-08-07 2015-07-08 Nagasaki University Therapeutischer oder prophylaktischer wirkstoff für generalisiertes schmerzsyndrom
US8455499B2 (en) 2008-12-11 2013-06-04 Amira Pharmaceuticals, Inc. Alkyne antagonists of lysophosphatidic acid receptors
GB2466121B (en) * 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2470833B (en) * 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
JP2013501064A (ja) 2009-08-04 2013-01-10 アミラ ファーマシューティカルス，インコーポレーテッド リゾホスファチジン酸受容体アンタゴニストとしての化合物
US8669246B2 (en) 2009-09-25 2014-03-11 Astellas Pharma Inc. Substituted amide compound
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
US9119878B2 (en) * 2010-07-08 2015-09-01 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
EP2611808B1 (de) 2010-09-02 2014-11-12 Merck Patent GmbH Pyrazolopyridinon-derivate als lpa-rezeptor-antagonisten
PH12012500542A1 (en) 2010-09-24 2012-11-12 Astellas Pharma Inc Substituted amide compound
EA201390821A1 (ru) 2010-12-07 2013-10-30 Амира Фармасьютикалс, Инк. Антагонисты рецепторов лизофосфатидной кислоты и их применение
ES2587856T3 (es) 2011-03-18 2016-10-27 Ono Pharmaceutical Co., Ltd. Derivado de tetrahidrocarbolina
CN103596947A (zh) 2011-04-05 2014-02-19 艾米拉医药股份有限公司 用于治疗纤维化、疼痛、癌症和呼吸、过敏性、神经系统疾病或心血管疾病的基于3-或5-联苯-4-基异噁唑的化合物
AU2012340698A1 (en) 2011-11-22 2014-04-24 Intermune, Inc. Methods of diagnosing and treating idiopathic pulmonary fibrosis
CA2896701C (en) 2012-12-28 2020-10-06 Ube Industries, Ltd. Halogen-substituted heterocyclic compound
US10596127B2 (en) * 2013-03-14 2020-03-24 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
DK2988743T3 (da) 2013-03-15 2021-03-01 Epigen Biosciences Inc Heterocykliske forbindelser, der kan anvendes til behandling af sygdom
CN106458964B (zh) 2014-06-27 2019-11-22 宇部兴产株式会社 卤素取代杂环化合物的盐
AR108838A1 (es) 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
ES2944304T3 (es) 2017-12-19 2023-06-20 Bristol Myers Squibb Co Pirazol azinas de ácido ciclohexílico como antagonistas de LPA
CA3085586C (en) 2017-12-19 2025-05-27 Bristol-Myers Squibb Company N-LINKED CARBAMOYL CYCLOHEXYL ACIDS TRIAZOLE USED AS LPA ANTAGONISTS
US11384067B2 (en) 2017-12-19 2022-07-12 Bristol-Myers Squibb Company Pyrazole n-linked carbamoyl cyclohexyl acids as LPA antagonists
JP7369125B2 (ja) 2017-12-19 2023-10-25 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのイソキサゾールｏ－架橋カルバモイルシクロヘキシル酸
ES2942767T3 (es) 2017-12-19 2023-06-06 Bristol Myers Squibb Co Isoxazol azoles del ácido ciclohexílico como antagonistas del LPA
EP3728196B1 (de) 2017-12-19 2023-04-05 Bristol-Myers Squibb Company Pyrazol-o-verknüpfte carbamoylcyclohexylsäuren als lpa-antagonisten
EP3728210B1 (de) 2017-12-19 2026-02-11 Bristol-Myers Squibb Company Isoxazol-n-verknüpfte carbamoylcyclohexylsäuren als lpa-antagonisten
JP7280881B2 (ja) 2017-12-19 2023-05-24 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのシクロヘキシル酸トリアゾールアゾール
WO2019126103A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Cyclohexyl acid pyrazole azoles as lpa antagonists
EP3728223B1 (de) 2017-12-19 2022-12-28 Bristol-Myers Squibb Company Cyclohexyl-säure-triazolazine als lpa-antagonisten
CN111479807B (zh) 2017-12-19 2024-11-26 百时美施贵宝公司 作为lpa拮抗剂的环己基酸异噁唑吖嗪
KR102062052B1 (ko) * 2018-03-20 2020-01-03 일양약품주식회사 베타네콜 서방성 제제 및 이의 제조방법
RS63990B1 (sr) 2018-06-07 2023-03-31 Idorsia Pharmaceuticals Ltd Alkoksi-supstituisani derivati piridinila kao antagonisti lpa1 receptora i njihova upotreba u lečenju fibroze
JP7427658B2 (ja) 2018-09-18 2024-02-05 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのシクロペンチル酸
US12428430B2 (en) 2018-09-18 2025-09-30 Bristol-Myers Squibb Company Oxabicyclo acids as LPA antagonists
KR102800284B1 (ko) 2018-09-18 2025-04-23 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 시클로헵틸 산
ES3054967T3 (en) 2019-06-18 2026-02-09 Bristol Myers Squibb Co Triazole carboxylic acids as lpa antagonists
JP7465899B2 (ja) 2019-06-18 2024-04-11 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのシクロブチルカルボン酸
KR20220024549A (ko) 2019-06-18 2022-03-03 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 이속사졸 카르복실산
AR119162A1 (es) 2019-06-18 2021-12-01 Idorsia Pharmaceuticals Ltd Derivados de piridin-3-ilo
IL289951B2 (en) 2019-07-30 2025-10-01 Taisho Pharmaceutical Co Ltd Urea compound as an LPA1 receptor antagonist
IL293474A (en) 2019-12-04 2022-08-01 Idorsia Pharmaceuticals Ltd Combination of lpa1 receptor antagonist aztidine with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases
KR20240068583A (ko) * 2020-08-11 2024-05-17 비바 스타 바이오사이언시스 리미티드 Lpa 수용체 길항제로서의 트리아졸-피리디닐 치환된 아자시클로헥실 아세트산 화합물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0653679B2 (ja) * 1987-11-11 1994-07-20 帝人株式会社 尿道内圧増強剤
US5677346A (en) * 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
AUPN862996A0 (en) * 1996-03-13 1996-04-04 Fujisawa Pharmaceutical Co., Ltd. A novel substituted-acetamide compound
IL120302A0 (en) 1996-03-27 1997-06-10 Pfizer Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
US6242572B1 (en) * 1997-05-13 2001-06-05 Smithkline Beecham Corporation Human G protein coupled lysophosphatidic acid receptor
JPH1135558A (ja) * 1997-07-18 1999-02-09 Zeria Pharmaceut Co Ltd ３−ベンゾイルインドール誘導体及びそれらを含有する医薬
EP1036178A1 (de) * 1997-12-30 2000-09-20 Allelix Biopharmaceuticals Inc. Identifizierung von lysolipid-rezeptoren zur förderung des entzundlichen antwortes
IL132406A0 (en) * 1998-10-21 2001-03-19 Pfizer Prod Inc Treatment of bph with cgmp elevators
JP4324266B2 (ja) * 1999-02-26 2009-09-02 キッセイ薬品工業株式会社 α１Ａアドレナリン受容体の変異体、当該変異体を用いた測定方法及び前立腺肥大に伴う排尿困難症治療剤
DE60137405D1 (de) 2000-02-18 2009-03-05 Kyowa Hakko Kirin Co Ltd Isoxazol- und thiazolverbindungen und ihre verwendung als medikamente
DK1263752T3 (da) * 2000-03-17 2008-04-14 Univ Tennessee Res Corp LPA-receptoragonister og -antagonister og fremgangsmåde til anvendelse heraf
US7012075B2 (en) * 2001-03-02 2006-03-14 Merck & Co., Inc. Cathepsin cysteine protease inhibitors

Also Published As

Publication number Publication date
EP1364659A4 (de) 2006-03-29
US20040067908A1 (en) 2004-04-08
EP1364659A1 (de) 2003-11-26
EP1364659B1 (de) 2009-11-11
WO2002062389A1 (en) 2002-08-15
US7288558B2 (en) 2007-10-30
JPWO2002062389A1 (ja) 2004-06-03
DE60234318D1 (de) 2009-12-24
JP4396808B2 (ja) 2010-01-13

Similar Documents

Publication Publication Date Title
ATE447970T1 (de) Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
ATE208210T1 (de) Kombination von proteintyrosin-kinaseinhibitoren und chemischer kastration zur behandlung von prostatakrebs
NO20071042L (no) 5-substituerte 2-fenylaminobenzamider som MEK-inhibitorer
DE69512930D1 (de) Stilben-derivate verwendbar als cyclooxygenase-2 hemmer
DE60205776T2 (de) Indolinon-derivative als protein-kinasehemmer
ATE517861T1 (de) Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
ATE501722T1 (de) Therapeutische behandlung androgenrezeptorbedingter leiden
DE69706660D1 (de) N-aminoalkyldibenzofuran-carboxamide als dopaminrezeptor-subtyp spezifische liganden
BR0109211A (pt) Compostos com atividade 5-ht1a úteis para o tratamento de distúrbios da retina externa
PT1267869E (pt) Antogonistas de receptor de glutamato metabotropico para o tratamento de tolerancia e de dependencia
EA200601378A1 (ru) Гидроизоиндолиновые антагонисты рецептора тахикинина
DE60219614D1 (de) 3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes
ATE201676T1 (de) N-azacycloalkylalkyldibenzothiophencarboxamide: spezifische liganden für dopaminrezeptorsubtypen
DE60234919D1 (de) 3, 7 oder 3 und 7 thia- oder oxaprostansäure derivate als mittel zur senkung des augeninnendrucks
DE602004023762D1 (de) Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3-thiosubstituierte indol-2-alkinsäuren
ATE287886T1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b) pyridinen als cyclin- abhängige kinase-hemmer
DE60313603D1 (de) Pharmazeutische kombination zur behandlung von benigner prostatahyperplasie oder zur langzeitvorbeugung von akuter harnzurückhaltung
AU2002321232A1 (en) Treatment of hair follicle with neurokinin 1 receptor antagonists
ATE369348T1 (de) Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
ATE550039T1 (de) Mittel zur behandlung von glomerulären erkrankungen
DE60121459D1 (de) Cyanidinmischung zur behandlung von dickdarmkrebs
DE60209886D1 (de) Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen
ATE282602T1 (de) Buttersäure matrix-metalloproteinase-inhibitoren
ATE535242T1 (de) Medizinische zusammensetzung zur prävention des übergangs zu einer operativen behandlung bei prostatahypertrophie

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties